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TO THE EDITOR
A variety of drugs are photosensitizing,
including psoralens, antibiotics (e.g.,
tetracyclines), fluoroquinolones,
phenylproprionic acid-derived non-
steroidal anti-inflammatory agents, phe-
nothiazines, and amiodarone (Gould
et al., 1995; Bellaney et al., 1996;
Stern, 1998; Epstein, 1999). In the
presence of solar or artificial UVR
exposure, these agents can induce an
erythemal and edemal response resem-
bling a severe sunburn along with
sustained hyperpigmentation (Gould
et al., 1995). Photosensitizing agents,
in particular fluoroquinolone anti-
biotics, induced benign and malignant
skin lesions, and specifically squamous
cell carcinomas (SCCs) in animal ex-
periments using UVR (Makinen et al.,
1997; Stern, 1998). Despite the poten-
tial for photosensitizing agents to en-
hance UVR-related skin cancers,
surprisingly little epidemiologic data
exist on this issue apart from the well-
established association with PUVA
(psoralen with UVA) therapy (e.g.,
Stern, 1998; Placzek et al., 1999).
As part of our population-based
case–control study from New Hamp-
shire, we asked subjects whether they
used any medicines that may have
caused their skin to be unusually
sensitive to the sun, using a standar-
dized questionnaire instrument (Kricker
et al., 1993, Supplementary text).
Further, we asked them the name of
the medicine prescribed, how long
altogether they took the medication,
and to describe any reaction to
the medicine they had, if any. Each
participant provided informed consent
in accordance with the Committee for
the Protection of Human Subjects at
Dartmouth College, which adheres to
the Declaration of Helsinki Principles.
We excluded subjects with unknown
responses (12 subjects), those who
reported UV treatment (9 subjects),
and those who used 5-fluorouracil or
Accutane because of the potential for
confounding by indication (e.g., the use
of this drug to treat early or precursor
SCCs; 22 subjects), leaving 1,395 cases
and controls in the analysis.
We began by analyzing whether
reported use of photosensitizing medi-
cines was related to any of the known
risk factors for skin cancer to evaluate
the possibility of reporting bias (e.g.,
among those with a photosensitive
phenotype) or confounding (Table 1).
Those who reported using photosensi-
tizing medicines tended to be younger,
and a higher proportion were women.
Taking into account age, gender, and
skin sensitivity to sunlight in our analy-
sis, we computed the odds ratio (OR)
and 95% confidence interval (CI) of
basal cell carcinoma (BCC) and SCC
associated with reported use of photo-
sensitizing agents before the reference
date using unconditional logistic regres-
sion (Breslow and Day, 1980) with the
statistical software SAS and PROC
LOGISTIC (SAS version 9.1.3 Service
Pack 4, Copyright (c) 2002–2003 by
SAS Institute Inc., Cary, NC). Addition-
ally, we estimated the ORs for photo-
sensitizing drug use stratified by the
other factors and tested for interactions
using the likelihood ratio test by in-
cluding an interaction term along with
the main effects term in the logistic
regression model (Breslow and Day,
1980).
Reported use of a photosensitizing
medicine was associated with an in-
creased risk of both BCC (OR¼ 1.5,
95% CI¼1.0–2.4) and SCC (OR¼ 1.8,
95% CI¼1.1–3.2) (Table 2). The ORs
for BCC and SCC were greater among
those with a longer duration of use
(BCC OR 41 year¼ 1.9, 95%
CI¼1.1–3.3, P for trend¼0.02 and
SCC OR 41¼ 2.3, 95% CI¼ 1.1–4.5,
P for trend¼0.16) (Table 2).
In a letter to the editor, a case–-
control comparison was made regard-
ing the use of photosensitizing drugs in
the past 5 years on 68 consecutive
patients attending a dermatologic clinic
who were over the age of 60 (Placzek
et al., 1999). Use of photosensitizing
drugs (for 5 or more years) was strongly
associated with actinic keratosis, a
putative precursor lesion to SCC
(OR¼8.1, Po0.01) (Placzek et al.,
1999). The prevalence of tetracycline
and aspirin (combined) was similar
among BCC cases and controls in a
study conducted by Wei et al. (1994);
however, the result is difficult to inter-
pret because aspirin has potential che-
mopreventive effects (Butler et al.,
2005) and is not generally regarded as
photosensitizing.
Several important limitations of our
study must also be kept in mind.
Notably, we asked subjects whether
they had ever used a medicine that
made their skin unusually sensitive to
the sun. Thus, a possible source of bias
in our study is that individuals who
have a sun-sensitive phenotype, and
hence are at greater risk of skin cancers,
were more likely to report use of
photosensitizing agents. If true, we
would likely observe that a higher
percentage of those who reported using
a photosensitizing medicine had a sun-
sensitive phenotype (i.e., be more likely
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Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; OR, odds ratio; SCC, squamous cell
carcinoma
to experience a response). An advan-
tage of our study is that we collected
detailed information about the study
participants; however, we did not find
differences in reporting between those
with and those without sun sensitivity.
The possibility of confounding by con-
dition or selection bias also cannot be
fully excluded, that is, the participants
differed from non-participants with
respect to photosensitizing drug use. In
our study, the factors most related to
reported use of these agents (i.e., age
and gender) did not appreciably differ
between participants and the pool of
potentially eligible subjects (data not
shown).
Our data in other respects support
the possibility of an effect of photo-
sensitizing medicine on skin cancer
risk. The medicines reported by sub-
jects covered those reported in the
literature as phototoxic, such as tetra-
cycline, deoxycline, fluoroquinolones,
sulfonamides, aryl proprionic acid
derivatives, hydrochlorothiazide, anti-
neoplastics, and phenothiazines (Table
S1). Our analysis was based on self-
reported use of a medicine that made
their skin sensitive to the sun. When we
restricted the analysis to those who
specifically reported medicines with
photosensitizing properties according
to the published literature, the ORs
were 1.86 (95% CI¼ 0.97–3.58) for
BCC and 1.62 (95% CI¼ 0.66–3.95)
for SCC. Further restriction to medi-
cines with phototoxic properties gave
similar results (OR for BCC¼ 1.78, 95%
CI¼0.92–3.43 and OR for SCC¼1.75,
95% CI¼ 0.74–4.16). (A list of specific
medicines reported by subjects that we
considered as photosensitizing are pro-
vided as Supplementary data.) Also, the
types of reactions reported were those
indicative of photosensitivity, for exam-
ple, sunburns, rashes, or other pigmen-
tary changes. We found associations to
be stronger among those with a history
of radiotherapy (OR for BCC¼ 5.3,
95% CI¼0.6–45.7 and OR for
SCC¼ 13.1, 95% CI¼ 1.2–142.2).
Although these results lack statistical
precision, they are consistent with
findings from the US PUVA Followup
Study, which observed synergistic
effects with both ionizing radiation
treatment and sun-sensitive skin type
(Stern et al., 1979).
Clearly many questions regarding
the adverse effects of photosensitizing
agents remain unanswered. Although
preliminary, our findings provide evi-
dence of the potential for photosensitiz-
ing agents to increase skin cancer
incidence. The reported incidence rates
of BCC and SCC are increasing rapidly
worldwide, and sunlight exposure is the
major environmental determinant of
these malignancies. In light of the
widespread use of photosensitizing
agents, heightened counseling on sun
Table 1. Selected characteristics according to use of photosensitizing
drugs among controls subjects (n=532)
Use of photosensitizing drugs for 41 month
No (n=497) Yes (n=35)
Characteristic1 n (%) n (%)
Age (years)
p50 102 (20.5) 9 (25.7)
51–60 88 (17.7) 12 (34.3)
61–70 212 (42.7) 11 (31.4)
470 95 (19.1) 3 (8.6)
Gender
Men 306 (61.6) 14 (40.0)
Women 191 (38.4) 21 (60.0)
Education
High school or less 246 (49.6) 13 (37.1)
Some college 155 (31.3) 13 (37.1)
College degree or professional school 95 (19.2) 9 (25.7)
Sun sensitivity
Tends to tan 334 (67.6) 24 (68.6)
Tends to burn 160 (32.4) 11 (31.4)
Lifetime no. of painful sunburns
0 151 (31.3) 12 (35.3)
1 91 (18.8) 8 (23.5)
2 57 (11.8) 2 (5.9)
X3 184 (38.1) 12 (35.3)
Radiation treatment2
No 458 (92.5) 33 (97.1)
Yes 37 (7.5) 1 (2.9)
Use of tanning lamp
No 430 (86.5) 28 (80.0)
Yes 67 (13.5) 7 (20.0)
1Data were missing on level of education (1 non-user), skin reaction to acute sun (3 non-users), and
lifetime sunburns (14 non-users, 1 user), and 23 subjects are not included because they were radiated
for skin cancer (2 non-users, 1 user).
2Three subjects were excluded because they were irradiated for skin cancer (2 non-users, 1 user).
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avoidance may be essential to prevent
subsequent occurrence of skin cancer
in patients requiring these medications
in the general population.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We are indebted to the dermatologists comprising
the New Hampshire Skin Cancer Study Group, the
New Hampshire Dermatological Society, and the
study staff and participants of the New Hampshire
Health Study. This study was funded by Grant
CA57494 of the National Cancer Institute.
Margaret R. Karagas1, Therese A.
Stukel1,2, Virginia Umland1, Maria M.
Tsoukas3, Leila A. Mott1, Henrik T.
Sorensen4, Annette O. Jensen5,
Heather H. Nelson6, Steven K.
Spencer7, Ann E. Perry8 and
Robert S. Stern9
1Department of Community and Family
Medicine, and the Norris Cotton Cancer
Center, Dartmouth Medical School, Lebanon,
New Hampshire, USA; 2Institute for Clinical
Evaluative Sciences, Toronto, Ontario, Canada;
3Section of Dermatology, University of
Chicago, Chicago, Illinois, USA; 4Department
of Clinical Epidemiology, Aarhus University
Hospital, 8000 Aarhus C, Denmark;
5Departments of Dermatology and Clinical
Epidemiology, Aarhus University Hospital,
8000 Aarhus C, Denmark; 6Department of
Environmental Health, Harvard School of
Public Health, Boston, Massachusetts, USA;
7Department of Medicine, Section of
Dermatology, Dartmouth Hitchcock Medical
Center, Lebanon, New Hampshire, USA;
8Department of Pathology, Dartmouth
Hitchcock Medical Center, Lebanon, New
Hampshire, USA and 9Department of
Dermatology, Beth Israel Deaconess Medical
Center Harvard Medical School, Boston,
Massachusetts, USA
E-mail: margaret.karagas@dartmouth.edu
SUPPLEMENTARY MATERIAL
Table S1. Frequency of use of specific photo-
sensitizing medications reported by study sub-
jects.
Supplementary text.
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Table 2. Odds ratios (95% CI) for BCC and SCC in relation to photosensitizing drug use
Controls BCC SCC
n (%) n (%) OR1 (95% CI) n (%) OR1 (95% CI)
Reported use of photosensitizing drug for 41 month
No 497 (93.4) 521 (89.5) 1.0 (ref) 254 (90.4) 1.0 (ref)
Yes 35 (6.6) 61 (10.5) 1.5 (1.0–2.4) 27 (9.6) 1.8 (1.1–3.2)
Duration of use
No use 497 (93.4) 521 (89.5) 1.0 (ref) 254 (90.4) 1.0 (ref)
p1 year 17 (3.2) 23 (4.0) 1.2 (0.6–2.3) 8 (2.9) 1.3 (0.5–3.1)
41 year 18 (3.4) 38 (6.5) 1.9 (1.0–3.3) 19 (6.8) 2.3 (1.1–4.5)
P for trend=0.02 P for trend=0.16
BCC, basal cell carcinoma; OR, odds ratio; SCC, squamous cell carcinoma.
1ORs adjusted for age, gender, and sun sensitivity as described in the text.
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